Bio-Rad Receives FDA Clearance for New BioPlex(R) 2200 System

Bio-Rad Receives FDA Clearance for New BioPlex(R) 2200 System
Novel Automated Multiplexing Technology Streamlines Patient Testing and
Maximizes Laboratory Efficiency 


HERCULES, Calif., Jan. 3  /PRNewswire-FirstCall/ -- Bio-Rad Laboratories, Inc.
(AMEX: BIO; BIOb), a multinational manufacturer and distributor of life science
research products and clinical diagnostics, announced today that it has
received marketing clearance from the U.S. Food and Drug Administration (FDA)
for its new BioPlex(R) 2200 system, a revolutionary new immunoassay platform
that employs multiplexing technology to analyze for multiple disease states
from single patient samples. It is the first clinical diagnostics platform to
offer multiplexing technology on a fully-automated, fully-integrated random
access platform. The system was unveiled last July at the American Association
of Clinical Chemistry meeting and will soon be available in the U.S.

"We are excited about receiving FDA clearance for this important new technology
and look forward to making it available to clinical laboratories. This unique
system will improve the quality of patient testing, decrease turnaround time
and eliminate the traditionally labor-intensive processes involved in specialty
diagnostics. The development of the BioPlex 2200 system is another example of
Bio-Rad's commitment to providing valuable tools that enable laboratories to
improve testing methods, maximize efficiencies and lower costs," said John
Goetz, Vice President of Bio-Rad's Clinical Diagnostics Group.

The BioPlex 2200 system is a fully automated bead-based multiplexing
immunoassay platform that can deliver up to 2200 results per hour. The system
will initially include a panel of assays targeting autoimmune diagnostics.
Future assays in development are in the areas of serology, infectious disease,
cardiac and toxicology.

Bio-Rad Laboratories, Inc. (http://www.bio-rad.com/) is a multinational
manufacturer and distributor of life science research products and clinical
diagnostics. It is based in Hercules, California, and serves more than 70,000
research and industry customers worldwide through a network of more than 30
wholly owned subsidiary offices.

Various statements made within this press release may constitute "forward-
looking statements" for purposes of the Securities and Exchange Commission's
"safe harbor" provisions under the Private Securities Litigation Reform Act of
1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-
looking statements contained herein involve risks and uncertainties that could
cause results to differ materially from the Company's expectations. 

DATASOURCE: Bio-Rad Laboratories, Inc.



CONTACT:  Susan Berg, Corporate Communications of Bio-Rad Laboratories,

Inc., [phone], or 



Web site:  http://www.bio-rad.com/ 

Copyright